Molecular profiling, also called biomarker testing or genomic profiling, looks at the specific gene changes and proteins inside your tumor. The results can tell your care team whether certain targeted therapies or immunotherapies may work for you, and whether clinical trials might be an option.

You received a report full of abbreviations: EGFR, MSI-H, TMB-H, PD-L1. It came with numbers and terms your oncologist knows well but that feel like a foreign language to you. That gap matters. Treatment decisions based on molecular profiling are among the most significant choices you may face. Understanding what you are looking at, even at a basic level, puts you in a better position to ask the right questions before you commit to a treatment path.

Before your tumor's genetic results arrived, the lab ran tests on tissue from your biopsy. Our guide on what happens in the lab after a biopsy walks through each stage if you want to understand that process first.

What is molecular profiling?

Every cancer is driven by changes in DNA: mutations, altered proteins, or other biological signals that tell cells to grow out of control. According to the National Cancer Institute, biomarker testing finds these specific changes inside your tumor to help guide treatment choices. It is the foundation of precision medicine, which tailors treatment to your cancer's biology instead of using a one-size-fits-all approach.

Profiling tests vary in scope. A small panel may check for 10 to 50 known mutations. A comprehensive genomic profile (CGP) analyzes hundreds of genes at once. Research in advanced non-small cell lung cancer showed that comprehensive profiling identified more actionable biomarkers and led to better real-world outcomes than smaller panels, according to a study in the Journal of Clinical Oncology. If your results feel incomplete or unclear, ask whether a broader test might help.

Why do doctors order this test?

The American Cancer Society says that molecular profiling is most commonly recommended when cancer has spread to other parts of the body or has returned after treatment. Your doctor may order it at diagnosis as a standard step for certain cancer types, including lung cancer, breast cancer, and colorectal cancer, where specific biomarkers connect to approved treatment options.

The reason is practical. Some therapies, particularly targeted therapies and certain immunotherapies, only work if your tumor has a particular biological feature. Testing first means your oncologist can match treatment to what is actually driving your cancer, not just where it is in your body.

The biomarkers patients see most often

Driver mutations

A driver mutation is a gene change that pushes your tumor to grow. When your report identifies one, it may mean a targeted therapy exists that is designed to block that specific driver. EGFR mutations and ALK gene fusions are common in non-small cell lung cancer. BRAF mutations appear in some melanomas and colorectal cancers. HER2 gene changes appear in breast cancer and some stomach cancers, among others.

Identifying a driver mutation is not the same as confirming a matched therapy is right for you. It depends on your cancer type, the exact variant found, and what is currently approved. A specialist with experience in your specific cancer type can tell you what the result means in your situation.

PD-L1 expression

PD-L1 is a protein on some cancer cells. When it appears at certain levels in your report, this may mean your immune system could respond to immunotherapy drugs that block the PD-1/PD-L1 pathway. Your report will usually give a percentage score. A higher score often, though not always, suggests a better chance of response. The relationship varies by cancer type, which is why context matters as much as the number itself.

MSI-H and dMMR

MSI-H stands for microsatellite instability-high. dMMR stands for deficient mismatch repair. Both terms describe the same problem: a breakdown in the tumor's ability to correct DNA copying errors, leaving the tumor with a large number of mutations. MSI-H status is a reliable predictor of response to certain immunotherapies across many cancer types, according to research - one of the most reliable markers across all cancer types.

Tumor mutational burden

Tumor mutational burden (TMB) measures the total number of mutations in your tumor's DNA. A high TMB score may mean the tumor has more unusual proteins that the immune system could recognize and attack. Like MSI-H, high TMB often suggests a greater chance of responding to some immunotherapy treatments, though it is one factor among many your oncologist will weigh, not a simple on-off signal.

Hormone receptor status and HER2

For breast cancer, molecular profiling routinely includes hormone receptor (HR) status, whether the tumor is estrogen-receptor positive (ER+), progesterone-receptor positive (PR+), or both, along with HER2 protein levels. These findings define the biological subtype of the breast cancer and drive some of the most fundamental treatment choices from the start. They are separate from hereditary gene tests like BRCA testing, which looks at inherited risk rather than the tumor's own biology.

What your results may mean for your options

When molecular profiling results come back, there are a few common outcomes.

An actionable result with an approved therapy. Your tumor has a known driver or biomarker, and a targeted therapy or immunotherapy approved for your cancer type and mutation exists. This is the most direct path molecular profiling can open. Your oncologist can discuss whether that option fits your overall situation.

A mutation with no approved therapy yet. The mutation is real and identified, but no standard treatment has been approved for it in your cancer type. This does not make the result useless. It may point toward clinical trials actively studying that specific marker. The ClinicalTrials.gov database lets you search by tumor type and genetic marker to find studies that may be relevant to you.

A variant of uncertain significance (VUS). Your report found a gene change, but the evidence is not yet strong enough to call it harmful or harmless. A VUS is not a reason for alarm on its own. Doctors may reclassify some variants over time as research continues. Your care team may discuss whether follow-up testing or a molecular tumor board review might help.

No actionable mutations found. This does not mean treatment options have disappeared. Targeted therapies designed for specific mutations may not apply, but immunotherapy based on PD-L1, MSI-H, or TMB may still be relevant. Chemotherapy and other approaches remain on the table. The profiling was still valuable because it showed which paths won't work and which might.

For a closer look at how biomarker results shape the choice between immunotherapy, targeted therapy, and chemotherapy in one of the most studied cancer types, see our article on how lung cancer treatment decisions are guided by tumor profile.

Should you ask for a more comprehensive test?

If your initial profiling used a small panel and results showed limited findings, ask your oncologist whether a comprehensive genomic profile would give a fuller picture. CGP tests examine far more genes and may identify actionable markers a smaller test would miss. This conversation is worth having before you finalize your treatment plan, not after. Some specialist centers and online oncology platforms can help arrange a CGP as part of a broader case review.

When a second opinion on your molecular results makes sense

Molecular profiling is one of the areas where specialist expertise makes the biggest practical difference. Oncologists who focus on a specific cancer type often have deep experience with particular mutations and know which details matter most. Molecular tumor boards, groups of specialists who review complex genomic findings together, exist at major cancer centers and routinely update treatment recommendations when they take a closer look at a case.

A second opinion focused on your molecular results is worth considering if:

• Your report includes a rare mutation your current oncologist has rarely seen.
• Your results include a variant of uncertain significance.
• Your results showed no actionable findings and you're unsure whether your doctor should order a more comprehensive test.
• Your proposed treatment plan does not seem to directly account for your biomarker findings.
• You want independent confirmation from a specialist before committing to a major treatment path.

Getting a second opinion is a normal part of good cancer care, not a challenge to your current doctor. You can upload your molecular profiling report and pathology records to HealthUnwired and connect with a verified oncologist by video within 48 hours, without travel. Many patients use this step to get a specialist's interpretation of complex results before they commit to a treatment decision.

For help building your list of questions before any oncology appointment, see our guide on what to ask your oncologist at your first appointment.

Practical steps to take right now

• Keep a copy of your full molecular profiling report. You'll need it for any second opinion or clinical trial application.
• Ask your oncologist whether your test was a small panel or a comprehensive genomic profile.
• Ask whether an approved therapy exists for your specific mutation in your cancer type.
• Ask whether any clinical trials are open for your biomarker result.
• If your report includes a VUS, ask what follow-up review is planned.
• If results feel unclear after your appointment, arrange a specialist second opinion before committing to a treatment plan.

When to talk to your doctor

Talk to your oncologist as soon as your molecular profiling results are in, ideally before you finalize treatment decisions. If your results include rare mutations, variants of uncertain significance, or other unclear findings, ask about tumor board review or a specialist second opinion. If your profiling used only a small panel, ask whether a comprehensive genomic profile would give a more complete picture of your cancer before treatment begins.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.